ArticleThe Annals of pharmacotherapy2023
Comment: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.
Rujittika PhD Mungmunpuntipantip et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it